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Abstract
The aim of this study is to determine if ultraviolet light (UVC) irradiation in combination with fluorescence-guided surgery
(FGS) can eradicate metastatic human pancreatic cancer in orthotopic nude–mouse models. Two weeks after orthotopic
implantation of human MiaPaCa-2 pancreatic cancer cells, expressing green fluorescent protein (GFP), in nude mice, bright-
light surgery (BLS) was performed on all tumor-bearing mice (n = 24). After BLS, mice were randomized into 3 treatment
groups; BLS-only (n = 8) or FGS (n = 8) or FGS-UVC (n = 8). The residual tumors were resected using a hand-held portable
imaging system under fluorescence navigation in mice treated with FGS and FGS-UVC. The surgical resection bed was
irradiated with 2700 J/m2 UVC (254 nm) in the mice treated with FGS-UVC. The average residual tumor area after FGS
(n = 16) was significantly smaller than after BLS only (n = 24) (0.13560.137 mm2 and 3.33862.929 mm2, respectively;
p= 0.007). The BLS treated mice had significantly reduced survival compared to FGS- and FGS-UVC-treated mice for both
relapse-free survival (RFS) (p,0.001 and p,0.001, respectively) and overall survival (OS) (p,0.001 and p,0.001,
respectively). FGS-UVC-treated mice had increased RFS and OS compared to FGS-only treated mice (p= 0.008 and p= 0.025,
respectively); with RFS lasting at least 150 days indicating the animals were cured. The results of the present study suggest
that UVC irradiation in combination with FGS has clinical potential to increase survival.
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Introduction
Complete tumor resection can improve overall survival of
pancreatic cancer patients [1], which is presently 5% at five years.
Metastatic relapse often occurs following attempted curative
resection of the primary tumor, because all cancer cells are not
removed by the surgeon due to the inability to see them. Making
tumors fluoresce offers great advantages for tumor detection
during surgery to achieve complete resection [2]. We have
previously showed that fluorescence-guided surgery (FGS) for
pancreatic cancer decreased the residual tumor burden and
improved overall and disease-free survival in mouse models [3–5].
However, it is difficult to remove all microscopic disease even with
FGS [5].
Ultraviolet (UV) light irradiation has shown efficacy in different
mouse models in our laboratory in vitro and in vivo on cancer
cells expressing fluorescent proteins [6–10]. We previously
reported UV-induced cancer cell death was found to be wave-
length and dose dependent as well as cell-line dependent, with
UVC being most effective [9]. In vitro, as little as 25 J/m2 UVC
irradiation killed approximately 70% of 143B human osteosarco-
ma cells expressing green fluorescent protein (GFP) and red
fluorescent protein (RFP). Cell death began approximately 4 h
after irradiation and continued until 10 h after irradiation. UVC
exposure also suppressed cancer cell growth in nude mice in a
model of minimal residual cancer (MRC) [7,9]. We also showed
that murine Lewis lung carcinoma (LLC) and human U87 glioma
cells, expressing GFP in the nucleus and RFP in the cytoplasm,
were more sensitive to UVC light than non-colored LLC and U87
cells, suggesting that the expression of fluorescent proteins in
cancer cells can enhance the photodynamic effect of UVC on
cancer cells.
In the present study, we demonstrated that UVC irradiation
used to irradicate MRC after FGS is more effective for human
pancreatic cancer in orthotopic mouse models than FGS alone,
and results in apparent cures.
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Materials and Methods
Establishment of Green Fluorescent Protein Labeled
Cancer Cell Line
For green fluorescent protein (GFP) gene transduction of cancer
cells, 70% confluent MiaPaCa-2 human pancreatic cancer cells
[11,12] were used. In brief, cells were incubated with a 1:1
precipitated mixture of retroviral supernatants of PT67-GFP cells
which express the GFP gene linked to the G418 resistance gene
and RPMI 1640 medium (Irvine Scientific, Santa Ana, CA)
containing 10% fetal bovine serum (FBS) (Hyclone Laboratories,
Logan, UT) for 72 h. Fresh medium was replenished at this time.
Cells were harvested with trypsin/EDTA 72 h post-transduction
and subcultured at a ratio of 1:15 into medium, which contained
200 mg/ml of the selective agent G418. The level of G418 was
increased stepwise up to 800 mg/ml [11,13–15].
Cell Culture
MiaPaCa-2-GFP and BxPC-3 [16] human pancreatic cancer
cells were maintained in RPMI 1640 medium supplemented with
10% FBS. The cells were incubated at 37uC in a humidified
atmosphere of 5% CO2 in air. The cells were collected after
trypsinization and stained with trypan blue (Sigma-Aldrich, St.
Louis, MO). Only viable cells which excluded trypan blue were
counted with a hemocytometer (Hausser Scientific, Horsham, PA).
Animals
Athymic nu/nu nude mice (AntiCancer Inc., San Diego, CA), 4–
6 weeks old, were used in this study. Mice were kept in a barrier
facility under HEPA filtration. Mice were fed with autoclaved
laboratory rodent diet. All mouse surgical procedures and imaging
were performed with the animals anesthetized by intramuscular
injection of a 0.02 ml solution of 50% ketamine, 38% xylazine,
and 12% acepromazine maleate. All animal studies were
conducted with an AntiCancer Institutional Animal Care and
Use Committee (IACUC)-protocol specifically approved for this
study and in accordance with the principles and procedures
outlined in the National Institute of Health Guide for the Care and
Use of Animals under Assurance Number A3873-1.
Subcutaneous Tumor Cell Implantation
MiaPaCa-2-GFP cells were harvested by trypsinization and
washed twice with serum-free medium. Cells (26106 in 100 mL
serum-free medium) were injected subcutaneously within 30 min
of harvesting, over the right and left flanks in male nude mice.
Subcutaneous tumors were allowed to grow for 2–4 weeks until
large enough to supply adequate tumor to harvest for subsequent
orthotopic implantation.
Orthotopic Tumor Implantation
A small 6- to 10-mm transverse incision was made on the left
flank of the mouse through the skin and peritoneum. The tail of
the pancreas was exposed through this incision, and a single tumor
fragment (3-mm3) from subcutaneous tumors was sutured to the
tail of the pancreas using 8-0 nylon surgical sutures (Ethilon;
Ethicon Inc., NJ, USA). On completion, the tail of the pancreas
was returned to the abdomen, and the incision was closed in one
layer using 6-0 nylon surgical sutures (Ethilon) [17–19].
Fluorescence Imaging
The Olympus OV100 Small Animal Imaging System (Olympus
Corp.), containing an MT-20 light source (Olympus Biosystems,
Planegg, Germany) and DP70 CCD camera (Olympus Corp.,
Tokyo, Japan) [20] and the Dino-Lite imaging system (AM4113T-
GFBW Dino-Lite Premier; AnMo Electronics Corporation,
Taiwan) [21] and the MVX10 long-working-distance microscope
(Olympus Corp.) [22], were used for imaging live mice. All images
were analyzed with ImageJ v1.440 (National Institutes of Health).
Tumor Resection and UVC Irradiation
Two weeks after orthotopic implantation of MiaPaCa-2-GFP
pancreatic cancer, bright-light surgery (BLS) was performed to all
tumor-bearing mice (n = 24). The exposed pancreatic tumor was
imaged preoperatively with the OV100 at a magnification of
0.14x. Resection of the primary pancreatic tumor was performed
under standard bright-field using the MVX10 microscope.
Postoperatively, the surgical resection bed was imaged with the
OV100 at a magnification of 0.56x to detect residual tumor. The
mice which underwent BLS were randomized into 3 treatment
groups: BLS-only (n = 8), FGS (n= 8), or FGS-UVC (n= 8) (Fig. 1).
The residual tumors of the FGS or FGS-UVC groups of mice were
resected using the Dino-Lite imaging system under fluorescence
navigation. After completion of FGS, the surgical resection bed
was imaged with the OV100 at a magnification of 0.89x to detect
microscopic minimal residual cancer (MRC) [23]. The surgical
resection bed of the FGS-UVC group of mice was irradiated with
2700 J/m2 UVC (emission peak 254 nm) from the bottom of the
chamber using a Benchtop 3UV transilluminator (UVP, LLC,
Upland, CA). The incision was closed in one layer using 6-0 nylon
surgical sutures. After treatment, the mice were allowed to recover
in their cages.
Noninvasive Imaging of Tumor Recurrence and
Progression
To assess for recurrence and to follow tumor progression
postoperatively, weekly non-invasive whole-body imaging of the
mice was performed with the OV100 at a magnification of 0.14x,
until the end of the experiment.
Monoclonal Antibody
Monoclonal antibodies specific for carcinoembryonic antigen
(CEA) were purchased from RayBiotech, Inc. (Norcross, GA). The
antibodies were conjugated with the Dylite 488 Protein Labeling
Kit (Molecular Probes Inc., Eugene, OR) according to the
manufacturers.
Sensitivity of Non-colored or Fluorescent Pancreatic
Cancer Cells to UVC Irradiation in vitro
To compare the efficacy of UVC irradiation on non-colored
BxPC-3 or fluorescent pancreatic cancer cells, BxPC-3 cells were
labeled with anti CEA antibody conjugated with Dylite 488
(BxPC-3-Ab488) or GFP (BxPC-3-GFP). BxPC-3-GFP or BxPC-
3-Ab488 or non-colored BxPC-3 cells (103) were plated in 100 ml
cell culture medium per well in 96-well plates. The cells were
irradiated with UVC at various doses (0, 25, 50 and 100 J/m2)
from a Benchtop 3UV transilluminator (UVP, LLC, Upland, CA).
Twenty hours after UVC irradiation, the cells were washed with
phosphate buffer saline (PBS) three times. The cell number was
determined with an IX71 fluorescence microscope (Olympus,
Tokyo, Japan).
Statistical Analysis
PASWStatistics 18.0 (SPSS, Inc) was used for statistical analyses.
Residual tumor area is expressed as mean 6 SD. The two-tailed
Student’s t-test was used to compare continuous variables between
2 groups. Kaplan–Meier survival curves were used for estimating
FGS and UVC Combination Cures Pancreatic Cancer
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survival. Survival outcomes were compared using log rank tests. A
p value,0.05 was considered statistically significant for all
comparisons.
Results
FGS Significantly Reduces Tumor Volume but does not
Eradicate All Residual Cancer Cells
BLS was performed on all tumor-bearing mice (n = 24). The
exposed pancreatic tumor was imaged preoperatively with the
OV100 at a magnification of 0.14x (Fig. 2A). Postoperatively, the
surgical resection bed was imaged with the OV100 at a
magnification of 0.56x (Fig. 2B) to detect unresected tumor. The
mice which underwent BLS were randomized into 3 treatment
groups; BLS-only (n = 8), FGS (n= 8), or FGS-UVC (n= 8) (Fig. 1).
Imaging was performed on all 24 animals after BLS and before
any other treatment. The average residual tumor area of each
group was 3.4663.45 mm2 (BLS), 3.2662.69 mm2 (FGS) or
3.3062.99 mm2 (FGS-UVC). The extent of residual disease was
statistically equivalent.
For FGS, the Dino-Lite hand-held portable imaging system was
used (Video S1). After completion of FGS, the surgical resection
bed was imaged with the OV100 at a magnification of 0.89x
(Fig. 2D) to detect microscopic MRC. MRC after BLS-only was
clearly detected with both the OV100 at a magnification of 0.56x
(Fig. 2B) and the Dino-Lite at a magnification of 30x (Fig. 2E).
MRC after FGS was marginally detected with either the OV100
at a magnification of 0.56x (Fig. 2C) or the Dino-Lite at a
magnification of 30x (Fig. 2F). The OV100 at high magnification
(0.89x) could readily detect microscopic MRC after FGS (Fig. 2D).
The average residual tumor area after FGS (n= 16) was
significantly smaller than BLS-only (n = 24) (0.13560.137 mm2
and 3.33862.929 mm2, respectively; p=0.007). These results
suggest that FGS significantly reduced the residual tumor volume
after BLS-only, but microscopic MRC remained on the surgical
bed even after FGS.
UVC Irradiation in Combination with FGS Cures
Metastatic Human Pancreatic Cancer
Recurrent tumors were detected with noninvasive whole-body
imaging at weeks 3 to 11 in the BLS-only treated mice and at
weeks 11 to 20 in the FGS-only treated mice (Fig. 3A and 4).
Recurrence was detected in the 8 mice (100%) in the BLS-only
group and 5 mice (62.5%) in the FGS group (Fig. 4). All recurrent
tumors progressed rapidly and metastasized regionally and
distantly and killed the mice between days 30 to 156 in the mice
treated with BLS-only and between days 134 to 195 in the mice
treated with FGS (Fig. 3B–3F and 4B). In contrast, no recurrence
or death were detected in any mice treated with FGS-UVC
(Fig. 3G–3J and 4B), suggesting that UVC irradiation eradicated
microscopic MRC after FGS.
Survival Impact of UVC Irradiation in Combination with
FGS
Relapse-free survival (RFS) and overall survival (OS) were
estimated in the 3 experimental groups of mice. As shown in
Figures 4A and 4B, 3-month RFS in mice after BLS-only, FGS
and FGS-UVC was 0%, 50% and 100%, respectively; and 5-
month OS was 10%, 90%, and 100%, respectively. Median RFS
in mice treated with BLS-only, FGS and FGS-UVC were 28 days,
103 days, and 138 days, respectively, and median OS was 57.5
days, 188.5 days, and 195 days, respectively (Table 1). Mice
treated with BLS-only showed significantly reduced survival
compared to mice treated with FGS and FGS-UVC for both
RFS (p,0.001 and p,0.001, respectively) and OS (p,0.001 and
Figure 1. Schematic diagram of the experimental protocol. Two weeks after orthotopic implantation of MiaPaCa-2-GFP pancreatic cancer,
bright-light surgery (BLS) was performed on all tumor-bearing mice (n = 24). Postoperatively, the surgical resection bed was imaged with the OV100
at a magnification of 0.56x to detect residual tumor. Mice which underwent BLS were randomized into 3 treatment groups: BLS-only (n = 8), FGS
(n = 8), or FGS-UVC (n = 8). Residual tumors in mice in the FGS and FGS-UVC groups were resected using the Dino-Lite imaging system under
fluorescence navigation. After completion of FGS, the surgical resection bed was imaged with the OV100 at a magnification of 0.89x to detect
micoscopic minimal residual cancer (MRC). The surgical resection bed in the mice in the FGS-UVC group was irradiated with 2700 J/m2 UVC (emission
peak, 254 nm) from the bottom of the chamber using a Benchtop 3UV transilluminator (UVP, LLC, Upland, CA).
doi:10.1371/journal.pone.0099977.g001
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p,0.001, respectively). FGS-UVC treated mice showed signifi-
cantly longer survival compared to mice treated with FGS for both
RFS and OS (p=0.008 and p=0.025, respectively) (Fig. 4 and
Table 1), suggesting that UVC irradiation in combination with
FGS eradicated microscopic MRC.
Efficacy of UVC Irradiation on Pancreatic Cancer Cells
Labeled with Anti-CEA Antibody Conjugated with Dylite
488 in vitro or GFP Compared to Unlabeled Cells
The efficacy of UVC irradiation on BxPC-3 pancreatic cancer
cells labeled with anti CEA antibody conjugated with Dylite
488(BxPC-3-Ab488), BxPC-3-GFP and unlabeled BxPC-3 was
compared (Fig. 5A). UVC was irradiated at various doses (0, 25,
50 and 100 J/m2). Compared to non-colored BxPC-3 cells, the
number of BxPC-3-Ab488 and BxPC-3-GFP cells decreased
significantly due to UVC irradiation with 25 J/m2 (p = 0.016 and
p= 0.01, respectively) and 50 J/m2 (p= 0.001 and p.0.001,
respectively). BxPC-3-Ab488 and BxPC-3-GFP cells were similarly
more sensitive to UVC light than non-colored BxPC-3 cells.
Discussion
The surgical orthotopic implantation (SOI) mouse model used
in the present study has been directly compared to clinical
outcome of the patient donors in a previous study of ours. Fresh
surgical specimens derived from patients with advanced stomach
cancer were orthotopically transplanted in nude mice using SOI.
There were statistically-significant correlations (p,0.01) for both
liver metastases and peritoneal involvement between patients and
mice [24].
In another previous study of ours, pancreatic-cancer specimens
were transplanted to the nude-mouse pancreas using SOI [25].
The resulting models represented clinical pancreatic cancer
including: extension of the locally growing human pancreatic
cancer to the nude-mouse stomach and duodenum; metastases to
the liver and regional lymph nodes; and distant metastases to the
adrenal gland, diaphragm, and mediastinal lymph nodes. The
transplanted human pancreatic tumors showed a similar pattern of
expression of human tumor-associated glycoprotein 72 and
carcinoembryonic antigen.
Figure 2. Preoperative and postoperative images of the orthotopic pancreatic cancer model (A–F). Upper panels are bright-field (BF),
and lower panels show tumor fluorescence. The residual tumor after BLS was clearly detected with both the OV100 at a magnification of 0.56x (B) and
the Dino-Lite at a magnification of 30x (E). The residual tumor after FGS was marginally detected with either the OV100 at a magnification of 0.56x (C)
or the Dino-Lite at a magnification of 30x (F). The OV100 at a magnification of 0.89x clearly detected the minimal residual tumor after FGS (D). (G) The
residual tumor area after FGS was significantly smaller than after BLS. All images were measured for residual tumor areas using ImageJ. **p,0.01.
doi:10.1371/journal.pone.0099977.g002
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We have previously shown that SOI of intact human stomach
cancer tissue resulted in the formation of metastases in 100% of
the mice with extensive primary growth to the regional lymph
nodes, liver, and lung. In contrast, orthotopic implantation of cell
suspensions of the same human stomach cancer at the same site,
metastases occurred in only 6.7% of the mice with local tumor
formation. These results emphasize the importance of using SOI
to allow full expression of metastatic potential [26].
We also previously compared the metastatic rate of human
renal cell carcinoma SN12C when transplanted by SOI or
orthotopic implantation of cell suspensions in the kidney.
Metastatic rates in the involved organs (lung, liver, and mediastinal
lymph nodes) were 2–3 fold higher with SOI compared to cellular
orthotopic implantation. Median survival time in the SOI model
was 40 days, which was significantly shorter than that of cellular
orthotopic implantation (68 days) [27].
In another of our previous studies, we compared SOI to cellular
orthotopic transplantation of bladder cancer. After SOI of the RT-
10 bladder tumor, metastases occurred in the regional and distant
lymph nodes, liver, pancreas, spleen, and tissue adjacent to the
adrenal gland and ureter, as well as the lungs. When disaggregated
RT-10 cells were injected transurethrally, no metastases formed
[28,29].
With regard to fidelity of drug response, in another previous
study of ours, cisplatin (CDDP) had significant efficacy on small-
cell lung cancer (SCLC) growing orthotopically in the lung and
mitomycin C (MMC) did not, which reflected the clinical
situation. In contrast, when the SCLC was growing subcutane-
ously, the tumors responded to MMC and not to CDDP. These
results indicated that the tumors growing orthotopically reflect the
clinical effects of drugs on human SCLC more closely than the
tumors growing subcutaneously [30]. Therefore, the SOI model
should not affect the UV sensitivity of the pancreatic cells as they
are growing on their natural orthotopic organ.
A major problem in surgical oncology is MRC after apparent
curative tumor resection [23]. We have previously demonstrated
the enhanced visualization and resection of primary and
metastatic cancer by FGS with the use of telomerase-dependent
adenovirus (OBP-401) that expresses the gfp gene only in cancer
cells which express the telomerase enzyme [31–33].
FGS studies have also been previously carried out in our
laboratory by labeling the tumors with tumor-specific fluorescent
antibodies which have direct clinical applicability [3–5,34–36].
A fluorophore-conjugated antibody to CEA was used to
evaluate FGS of pancreatic tumors in SOI mouse models of
human pancreatic cancer BxPC-3. After intravenous injection of
anti-CEA-Alexa Fluor 488, complete resection was achieved in
Figure 3. Representative time course of tumor recurrence after FGS. The recurrence was initially detected by non-invasive whole-body
imaging using the OV100 at a magnification of 0.14x at week 11 after FGS (A; white arrowhead). The recurrent tumor progressed rapidly (B–D) and
killed the mice by week 22 after FGS (D). Left axillary lymph-node metastasis (E; white arrowhead), large local recurrent tumor and many
disseminating tumor nodules (F) were detected in the mice at time of death. In contrast, no recurrence was detected in the FGS-UVC group (G–J).
Scale bars: 10 mm.
doi:10.1371/journal.pone.0099977.g003
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Figure 4. Relapse-free survival (RFS) (A) and overall survival (OS) (B) for tumor-bearing mice treated with BLS-only, FGS, or FGS-
UVC.
doi:10.1371/journal.pone.0099977.g004
Table 1. Relapse-free survival (RFS) and overall survival (OS) for tumor-bearing mice treated with BLS-only or FGS or FGS-UVC.
Treatment Median p-value Median p-value
RFS (days) (Log-Rank) OS (days) (Log-Rank)
BLS-only 28 – 57.5 –
FGS 103 p,0.001* 188.5 p,0.001*
FGS-UVC 138 p,0.001*, p= 0.008** 195 p,0.001*, p= 0.025**
*compared to BLS.
**compared to FGS.
doi:10.1371/journal.pone.0099977.t001
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92% of mice in the FGS group compared to 45.5% in the BLS
group. Cure rates with FGS compared to BLS improved from
4.5% to 40%, respectively, and 1-year postoperative survival rates
increased from 0% with BLS to 28% with FGS. Median DFS
increased from 5 weeks with BLS to 11 weeks with FGS. Median
OS increased from 13.5 weeks with BLS to 22 weeks with FGS
[37].
The results of these previous studies show the great potential of
FGS. However, technical problems remain to remove MRC after
FGS. In the present study, we demonstrated that the MRC
remained in the surgical bed even after FGS (Fig. 2D), which
progressed rapidly and could kill the animals (Fig. 3B–3F).
However, UVC irradiation in combination with FGS completely
prevented recurrence (Fig. 3G–3J and 4B) and showed signifi-
cantly increased survival compared to FGS alone for both RFS
Figure 5. Efficacy of UVC irradiation on non-colored BxPC-3, BxPC-3-Ab488 and BxPC-3-GFP in vitro. (A) Representative images of non-
colored BxPC-3, BxPC-3-Ab488 and BxPC-3-GFP in vitro. Cells were observed with the FV1000 confocal microscope (Olympus, Tokyo, Japan). Scale
bars: 50 mm. (B) UVC was irradiated at various doses (0, 25, 50 and 100 J/m2). Compared to non-colored BxPC-3 cells, the number of BxPC-3-Ab488
and BxPC-3-GFP cells decreased significantly due to UVC irradiation with 25 and 50 J/m2. The experimental data are expressed as the mean 6 SD.
*p,0.05, **p,0.01.
doi:10.1371/journal.pone.0099977.g005
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and OS (p=0.008 and p=0.025, respectively) (Fig. 4 and Table 1).
These results suggest that UVC irradiation could eradicate
microscopic MRC remaining after FGS.
We have previously shown that UVC irradiation is able to
penetrate up to 40 mm in three-dimensional histoculture using
Gelfoam and in an ex vivo tumor model, as well as kill superficial
cancer cells up to a depth of 40 mm in vivo without damage of deep
tissues [7]. In the present study, MRC was visualized, but only
under high magnification, after FGS (Fig. 2D). UVC was able to
eradicate the MRC without apparent side effects and eliminated
recurrence (Fig. 3G–3J and 4B). These results suggest that a depth
of 40 mm is of sufficient depth to eradicate microscopic MRC after
FGS. Thus UVC irradiation can sterilize the surgical resection bed
of cancer cells after FGS.
Furthermore, we have demonstrated in this study that BxPC-3-
Ab488 cells were more sensitive to UVC light than non-colored
BxPC-3 cells and equivalent in sensitivity to BxPC-3-GFP cells
(Fig. 5B). These results suggest that UVC irradiation could
eradicate microscopic MRC, labeled with an exogenous fluor-
ophore, after FGS and that the technology described in the present
report is applicable in clinical practice.
Supporting Information
Video S1 Resection of the residual tumor after BLS
under fluorescence navigation.
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